BVNR.Y Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.7.46 |
52 Week High | kr.10.65 |
52 Week Low | kr.5.95 |
Beta | 1.34 |
1 Month Change | -11.48% |
3 Month Change | -15.95% |
1 Year Change | -16.70% |
3 Year Change | -52.94% |
5 Year Change | 11.43% |
Change since IPO | 26.21% |
Recent News & Updates
Recent updates
Shareholder Returns
BVNR.Y | US Biotechs | US Market | |
---|---|---|---|
7D | -2.4% | -0.5% | 0.6% |
1Y | -16.7% | 9.6% | 29.5% |
Return vs Industry: BVNR.Y underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: BVNR.Y underperformed the US Market which returned 29.8% over the past year.
Price Volatility
BVNR.Y volatility | |
---|---|
BVNR.Y Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BVNR.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: BVNR.Y's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 1,379 | Paul Chaplin | https://www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
BVNR.Y fundamental statistics | |
---|---|
Market cap | US$1.76b |
Earnings (TTM) | US$214.18m |
Revenue (TTM) | US$1.03b |
8.2x
P/E Ratio1.7x
P/S RatioIs BVNR.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BVNR.Y income statement (TTM) | |
---|---|
Revenue | kr.7.06b |
Cost of Revenue | kr.1.90b |
Gross Profit | kr.5.16b |
Other Expenses | kr.3.69b |
Earnings | kr.1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | 18.93 |
Gross Margin | 73.07% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 0.2% |
How did BVNR.Y perform over the long term?
See historical performance and comparison